These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
194 related items for PubMed ID: 1412207
1. Formation of an association between factor XII and kallikrein in human plasma--significance of storage of plasma and the functional state of plasma kallikrein. Hoem NO, Johannesen S, Briseid K. Thromb Res; 1992 May 15; 66(4):421-34. PubMed ID: 1412207 [Abstract] [Full Text] [Related]
2. Functional correlation between kallikrein and factor XII activated in human plasma. Briseid K, Hoem NO, Johannesen S, Marthinsen K. Thromb Res; 1990 Mar 15; 57(6):945-56. PubMed ID: 1696402 [Abstract] [Full Text] [Related]
3. Contact activation factors in plasma from pregnant women--increased level of an association between factor XII and kallikrein. Briseid K, Hoem NO, Johannesen S, Fossum S. Thromb Res; 1991 Jan 15; 61(2):123-33. PubMed ID: 2020942 [Abstract] [Full Text] [Related]
4. Activation of factor XII in acetone-treated human plasma: significance of the functional state of plasma kallikrein for the extent of activation. Hoem NO, Briseid K. Acta Pharmacol Toxicol (Copenh); 1986 Aug 15; 59(2):144-50. PubMed ID: 3490738 [Abstract] [Full Text] [Related]
5. Amidolytic assay of factor XI in human plasma--significance of kallikrein for the activity measured. Briseid K, Hoem NO, Johannesen S, Haug K. Thromb Res; 1995 May 01; 78(3):239-50. PubMed ID: 7631304 [Abstract] [Full Text] [Related]
6. Contact activation factors in plasma from women using oral contraceptives--increased levels of factor XII, kinin-free high molecular weight kininogen and acetone-activated kallikrein. Hoem NO, Johannesen S, Hauge G, Rud AC, Sandem S, Briseid K. Thromb Res; 1991 Nov 15; 64(4):427-34. PubMed ID: 1788829 [Abstract] [Full Text] [Related]
14. Functional characterization of a variant factor XII (F XII Locarno) in a cross reacting material positive F XII deficient plasma. Wuillemin WA, Furlan M, Stricker H, Lämmle B. Thromb Haemost; 1992 Feb 03; 67(2):219-25. PubMed ID: 1621242 [Abstract] [Full Text] [Related]
15. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway. Kaplan AP, Joseph K. Adv Immunol; 2014 Feb 03; 121():41-89. PubMed ID: 24388213 [Abstract] [Full Text] [Related]
16. The levels of factor XIIa generated in human plasma on an electronegative surface are insensitive to wide variation in the concentration of FXII, prekallikrein, high molecular weight kininogen or FXI. Mitropoulos KA. Thromb Haemost; 1999 Sep 03; 82(3):1033-40. PubMed ID: 10494760 [Abstract] [Full Text] [Related]
18. Part of purified human plasma kallikrein removed together with a remaining IgG fraction--immunoblot experiments and functional tests. Briseid K, Johannesen S. Scand J Clin Lab Invest; 2002 Sep 03; 62(1):21-4. PubMed ID: 12002409 [Abstract] [Full Text] [Related]
20. Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor. Scott CF, Silver LD, Schapira M, Colman RW. J Clin Invest; 1984 Apr 03; 73(4):954-62. PubMed ID: 6561202 [Abstract] [Full Text] [Related] Page: [Next] [New Search]